【Delayed】Takara Bio has entered into a license agreement relating to C-REV with Tasly Biopharmaceuticals, China May 13, 2020May 13, 2020 by / Share This.....LinkedinTwitterFacebookGoogleEmail Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relstions Japanese Products Site サブ-ナビゲーション Top Management Policy Message from the President Formulation of Medium-Term Management Plan FY2020 Corporate Governance Business Risks Financial Data Financial Highlights Financial Indicators Cash Flow Business Segments IR Library Financial Results Presentation Materials Annual Report Stock Information General Meeting of Shareholders Shareholder Return / Dividends Stock Overview Stock Status Stock Price IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide 2020/05/13 Related News: [Delayed]Takara Bio Announces Transfer of SAKIGAKE…Takara Bio Group Formulated “Medium-Term Management…Takara Bio Report 2022Takara Bio Report 2023[Delayed] Corporate Governance Report[Delayed] Annual Securities Report for Fiscal Year…
